You are here: Industry Insights > ovarian cancer

News List

Pharmaceutical News of the Week (July. 13th-July. 17th) | PharmaSources.com - Updates on R&D PharmaSources/Caicai
July 22, 2020
With the third week of July coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions, and miscellany that happened during July 13-17, including 30 pieces.
FDA approves new imaging drug to identify ovarian cancer lesions EuropeanPharmaceuticalReview
December 01, 2021
The US Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions.
FDA Approves Cytalux Drugs
November 30, 2021
On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent imaging agents to target and illuminate cancer during surgery, today announced that the U.S. Food and Drug Administration (FDA)...
FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for Ovarian Cancer Treatment AmericanPharmaceuticalReview
October 28, 2021
Alkermes plc announced that the FDA has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy...
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer drugs
August 25, 2021
Sutro Biopharma today announced that the U.S.FDA has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC).
UT Southwestern finds crucial new molecular mechanisms and biomarkers in ovarian cancer firstwordpharma
August 02, 2021
UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.
BDR Pharma launches generic Rucaparib to treat advanced ovarian and prostate cancers expresspharma
May 31, 2021
BDR Pharmaceutical launched BDPARIB (Rucaparib) to treat advanced ovarian and prostate cancers.
Verastem Oncology with Breakthrough Therapy for Defactinib in Ovarian Cancer americanpharmaceuticalreview
May 28, 2021
Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile.
BeiGene’s ovarian cancer drug pamiparib gets conditional approval in China pharmaceutical-technology
May 11, 2021
Discovered by BeiGene researchers, pamiparib inhibits both PARP1 and PARP2. It is being developed as a monotherapy and combination therapy for various solid tumours.
Alkermes, Merck Enter Clinical Trial and Supply Agreement contractpharma
April 08, 2021
To evaluate nemvaleukin alfa in combination with Keytruda in patients with platinum-resistant ovarian cancer.

Previous page 1 2 3 4 5 6 7 8 Next page